Dr Gronchi speaks with ecancertv at ESMO 2016 about the responses of patients with advanced soft tissue sarcoma to adjuvant epirubicin plus ifosfamide compared to those receiving a tailored chemo regimen based on histology subgrouping

He reports significantly improved relapse-free survival and overall survival for patients receiving adjuvant chemo, thought notes the trial is a technical failure due to being powered for the histology-tailored sub types which did not show any benefit.

Dr Gronchi presented these results to the conference, with video available here, and the story is reported in ecancer news here.